Systematic Literature Review of Machine Learning Algorithms Using Pretherapy Radiologic Imaging for Glioma Molecular Subtype Prediction

References

1. 1.↵
   1. Norden AD,
   2. Wen PY

   . Glioma therapy in adults. Neurologist 2006;12:279–92 doi:10.1097/01.nrl.0000250928.26044.47 pmid:17122724

   CrossRefPubMedWeb of Science
2. 2.↵
   Johns Hopkins Medicine. Gliomas. June 27, 2022. https://www.hopkinsmedicine.org/health/conditions-and-diseases/gliomas. Accessed June 27, 2022
3. 3.↵
   1. Louis DN,
   2. Perry A,
   3. Wesseling P, et al

   . The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol 2021;23:1231–51 doi:10.1093/neuonc/noab106 pmid:34185076

   CrossRefPubMed
4. 4.↵
   1. Parker NR,
   2. Khong P,
   3. Parkinson JF, et al

   . Molecular heterogeneity in glioblastoma: potential clinical implications. Front Oncol 2015;5:55 doi:10.3389/fonc.2015.00055 pmid:25785247

   CrossRefPubMed
5. 5.↵
   1. Friedmann-Morvinski D

   . Glioblastoma heterogeneity and cancer cell plasticity. Crit Rev Oncog 2014;19:327–36 doi:10.1615/critrevoncog.2014011777 pmid:25404148

   CrossRefPubMed
6. 6.↵
   1. Olar A,
   2. Aldape KD

   . Using the molecular classification of glioblastoma to inform personalized treatment. J Pathol 2014;232:165–77 doi:10.1002/path.4282 pmid:24114756

   CrossRefPubMed
7. 7.↵
   1. Tillmanns N,
   2. Lum AE,
   3. Cassinelli S, et al

   . Identifying clinically applicable machine learning algorithms for glioma segmentation: recent advances and discoveries. Neurooncol Adv 2022;4:vdac093 doi:10.1093/noajnl/vdac093 pmid:36071926

   CrossRefPubMed
8. 8.↵
   1. Bakas S,
   2. Reyes M,
   3. Jakab A, et al

   . Identifying the Best Machine Learning Algorithms for Brain Tumor Segmentation: Progression Assessment, and Overall Survival Prediction in the BRATS Challenge. 2019. arxiv.org/abs/1811.02629. Accesed June 27, 2022
9. 9.↵
   1. Jekel L,
   2. Brim WR,
   3. von Reppert M, et al

   . Machine learning applications for differentiation of glioma from brain metastasis: a systematic review. Cancers(Basel) 2022;14:1369 doi:10.3390/cancers14061369 pmid:35326526

   CrossRefPubMed
10. 10.↵
    1. Cassinelli Petersen GI,
    2. Shatalov J,
    3. Verma T, et al

    . Machine learning in differentiating gliomas from primary CNS lymphomas: a systematic review, reporting quality, and risk of bias assessment. AJNR Am J Neuroradiol 2022;43:526–33 doi:10.3174/ajnr.A7473 pmid:35361577

    Abstract/FREE Full Text
11. 11.↵
    1. Bahar RC,
    2. Merkaj S,
    3. Cassinelli Petersen GI, et al

    . Machine learning models for classifying high- and low-grade gliomas: a systematic review and quality of reporting analysis. Front Oncol 2022;12:856231 doi:10.3389/fonc.2022.856231 pmid:35530302

    CrossRefPubMed
12. 12.↵
    1. Sanghani P,
    2. Ang BT,
    3. King NK, et al

    . Overall survival prediction in glioblastoma multiforme patients from volumetric, shape and texture features using machine learning. Surg Oncol 2018;27:709–14 doi:10.1016/j.suronc.2018.09.002 pmid:30449497

    CrossRefPubMed
13. 13.↵
    1. Bakas S,
    2. Shukla G,
    3. Akbari H, et al

    . Overall survival prediction in glioblastoma patients using structural magnetic resonance imaging (MRI): advanced radiomic features may compensate for lack of advanced MRI modalities. J Med Imaging (Bellingham) 2020;7:031505 doi:10.1117/1.JMI.7.3.031505 pmid:32566694

    CrossRefPubMed
14. 14.↵
    1. Clark K,
    2. Vendt B,
    3. Smith K, et al

    . The Cancer Imaging Archive (TCIA): maintaining and operating a public information repository. J Digit Imaging 2013;26:1045–57 doi:10.1007/s10278-013-9622-7 pmid:23884657

    CrossRefPubMedWeb of Science
15. 15.↵
    1. Heus P,
    2. Damen J,
    3. Pajouheshnia R, et al

    . Uniformity in measuring adherence to reporting guidelines: the example of TRIPOD for assessing completeness of reporting of prediction model studies. BMJ Open 2019;9:e025611 doi:10.1136/bmjopen-2018-025611 pmid:31023756

    Abstract/FREE Full Text
16. 16.↵
    1. Mongan J,
    2. Moy L,
    3. Kahn CE Jr.

    Checklist for Artificial Intelligence in Medical Imaging (CLAIM): a guide for authors and reviewers. Radiol Artif Intell 2020;2:e200029 doi:10.1148/ryai.2020200029 pmid:33937821

    CrossRefPubMed
17. 17.↵
    1. Moons KG,
    2. Wolff RF,
    3. Riley RD, et al

    . PROBAST: a tool to assess risk of bias and applicability of prediction model studies: explanation and elaboration. Ann Intern Med 2019;170:W1–33 doi:10.7326/M18-1377 pmid:30596876

    CrossRefPubMed
18. 18.↵
    1. Li YM,
    2. Suki D,
    3. Hess K, et al

    . The influence of maximum safe resection of glioblastoma on survival in 1229 patients: can we do better than gross-total resection? J Neurosurg 2016;124:977–88 doi:10.3171/2015.5.JNS142087 pmid:26495941

    CrossRefPubMed
19. 19.↵
    1. Hegi ME,
    2. Diserens AC,
    3. Gorlia T, et al

    . MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352:997–1003 doi:10.1056/NEJMoa043331 pmid:15758010

    CrossRefPubMedWeb of Science
20. 20.↵
    1. Fukuma R,
    2. Yanagisawa T,
    3. Kinoshita M, et al

    . Prediction of IDH and TERT promoter mutations in low-grade glioma from magnetic resonance images using a convolutional neural network. Sci Rep 2019;9:20311 doi:10.1038/s41598-019-56767-3 pmid:31889117

    CrossRefPubMed
21. 21.↵
    1. Ren Y,
    2. Zhang X,
    3. Rui W, et al

    . Noninvasive prediction of IDH1 mutation and ATRX expression loss in low-grade gliomas using multiparametric MR radiomic features. J Magn Reson Imaging 2019;49:808–17 doi:10.1002/jmri.26240 pmid:30194745

    CrossRefPubMed
22. 22.↵
    1. Zhang X,
    2. Tian Q,
    3. Wang L, et al

    . Radiomics strategy for molecular subtype stratification of lower-grade glioma: detecting IDH and TP53 mutations based on multimodal MRI. J Magn Reson Imaging 2018;48:916–26 doi:10.1002/jmri.25960 pmid:29394005

    CrossRefPubMed
23. 23.↵
    1. Gao M,
    2. Huang S,
    3. Pan X, et al

    . Machine learning-based radiomics predicting tumor grades and expression of multiple pathologic biomarkers in gliomas. Front Oncol 2020;10:1676 doi:10.3389/fonc.2020.01676 pmid:33014836

    CrossRefPubMed
24. 24.↵
    1. Lu CF,
    2. Hsu FT,
    3. Hsieh KL, et al

    . Machine learning-based radiomics for molecular subtyping of gliomas. Clin Cancer Res 2018;24:4429–36 doi:10.1158/1078-0432.CCR-17-3445 pmid:29789422

    Abstract/FREE Full Text
25. 25.↵
    1. Chen X,
    2. Zeng M,
    3. Tong Y, et al

    . Automatic prediction of MGMT status in glioblastoma via deep learning-based MR image analysis. Biomed Res Int 2020;2020:9258649 doi:10.1155/2020/9258649 pmid:33029531

    CrossRefPubMed
26. 26.↵
    1. Li Y,
    2. Wei D,
    3. Liu X, et al

    . Molecular subtyping of diffuse gliomas using magnetic resonance imaging: comparison and correlation between radiomics and deep learning. Eur Radiol 2022;32:747–58 doi:10.1007/s00330-021-08237-6 pmid:34417848

    CrossRefPubMed
27. 27.↵
    1. Hedyehzadeh M,
    2. Maghooli K,
    3. MomenGharibvand M, et al

    . A comparison of the efficiency of using a deep CNN approach with other common regression methods for the prediction of EGFR expression in glioblastoma patients. J Digit Imaging 2020;33:391–98 doi:10.1007/s10278-019-00290-4 pmid:31797142

    CrossRefPubMed
28. 28.↵
    1. Akbari H,
    2. Bakas S,
    3. Pisapia JM, et al

    . In vivo evaluation of EGFRvIII mutation in primary glioblastoma patients via complex multiparametric MRI signature. Neuro Oncol 2018;20:1068–79 doi:10.1093/neuonc/noy033 pmid:29617843

    CrossRefPubMed
29. 29.↵
    1. Park JE,
    2. Kim HS,
    3. Park SY, et al

    . Prediction of core signaling pathway by using diffusion- and perfusion-based MRI radiomics and next-generation sequencing in isocitrate dehydrogenase wild-type glioblastoma. Radiology 2020;294:388–97 doi:10.1148/radiol.2019190913 pmid:31845844

    CrossRefPubMed
30. 30.↵
    1. Sun Z,
    2. Li Y,
    3. Wang Y, et al

    . Radiogenomic analysis of vascular endothelial growth factor in patients with diffuse gliomas. Cancer Imaging 2019;19:68 doi:10.1186/s40644-019-0256-y pmid:31639060

    CrossRefPubMed
31. 31.↵
    1. Buda M,
    2. AlBadawy EA,
    3. Saha A, et al

    . Deep radiogenomics of lower-grade gliomas: convolutional neural networks predict tumor genomic subtypes using MR images. Radiol Artif Intell 2020;2:e180050 doi:10.1148/ryai.2019180050 pmid:33937809

    CrossRefPubMed
32. 32.↵
    1. Li Y,
    2. Liang Y,
    3. Sun Z, et al

    . Radiogenomic analysis of PTEN mutation in glioblastoma using preoperative multi-parametric magnetic resonance imaging. Neuroradiology 2019;61:1229–37 doi:10.1007/s00234-019-02244-7 pmid:31218383

    CrossRefPubMed
33. 33.↵
    1. Wagner MW,
    2. Hainc N,
    3. Khalvati F, et al

    . Radiomics of pediatric low-grade gliomas: toward a pretherapeutic differentiation of BRAF-mutated and BRAF-fused tumors. AJNR Am J Neuroradiol 2021;42:759–65 doi:10.3174/ajnr.A6998 pmid:33574103

    Abstract/FREE Full Text
34. 34.↵
    1. Jian A,
    2. Jang K,
    3. Manuguerra M, et al

    . Machine learning for the prediction of molecular markers in glioma on magnetic resonance imaging: a systematic review and meta-analysis. Neurosurgery 2021;89:31–44 doi:10.1093/neuros/nyab103 pmid:33826716

    CrossRefPubMed
35. 35.↵
    1. Cabitza F,
    2. Campagner A,
    3. Soares F, et al

    . The importance of being external. Methodological insights for the external validation of machine learning models in medicine. Comput Methods Programs Biomed 2021;208:106288 doi:10.1016/j.cmpb.2021.106288 pmid:34352688

    CrossRefPubMed
36. 36.↵
    1. Rieke N,
    2. Hancox J,
    3. Li W, et al

    . The future of digital health with federated learning. NPJ Digit Med 2020;3:119 doi:10.1038/s41746-020-00323-1 pmid:33015372

    CrossRefPubMed
37. 37.↵
    1. Sheller MJ,
    2. Edwards B,
    3. Reina GA, et al

    . Federated learning in medicine: facilitating multi-institutional collaborations without sharing patient data. Sci Rep 2020;10:12598 doi:10.1038/s41598-020-69250-1 pmid:32724046

    CrossRefPubMed
38. 38.↵
    1. Pfitzner B,
    2. Steckhan N,
    3. Arnrich B

    . Federated learning in a medical context: a systematic literature review. ACM Trans Internet Technol 2021;21:1–31 doi:10.1145/3412357

    CrossRef
39. 39.↵
    1. Baid U,
    2. Ghodasara S,
    3. Mohan S, et al

    . The RSNA-ASNR-MICCAI BraTS 2021 Benchmark on Brain Tumor Segmentation and Radiogenomic Classification. Computer Vision and Pattern Recognition. 2021. https://arxiv.org/abs/2107.02314. Accessed June 27, 2022
40. 40.↵
    1. Menze BH,
    2. Jakab A,
    3. Bauer S, et al

    . The Multimodal Brain Tumor Image Segmentation Benchmark (BRATS). IEEE Trans Med Imaging 2015;34:1993–2024 doi:10.1109/TMI.2014.2377694 pmid:25494501

    CrossRefPubMed
41. 41.↵
    1. Bakas S,
    2. Akbari H,
    3. Sotiras A, et al

    . Advancing The Cancer Genome Atlas glioma MRI collections with expert segmentation labels and radiomic features. Sci Data 2017;4:170117 doi:10.1038/sdata.2017.117 pmid:28872634

    CrossRefPubMed
42. 42.↵
    RSNA-MICCAI Brain Tumor Radiogenomic Classification. July 13, 2021 to October 15, 2021. https://www.kaggle.com/c/rsna-miccai-brain-tumor-radiogenomic-classification. Accessed June 27, 2022